Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - Authors' reply.

Voysey M. and Pollard AJ., (2021), Lancet, 397

Injection fears and COVID-19 vaccine hesitancy

FREEMAN D., (2021), Psychological Medicine

Time to integrate congenital CMV testing into hearing screening for newborn babies.

Kadambari S. and Andersson MI., (2021), Lancet, 397

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Barrett JR. et al, (2021), Nature medicine

Systems Immunology: Revealing Influenza Immunological Imprint

Tomic A. et al, (2021), Viruses, 13, 948 - 948

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Ahern DJ. et al, (2021)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.

Shaw RH. et al, (2021), Lancet

Natural Killer cells demonstrate distinct eQTL and transcriptome-wide disease associations, highlighting their role in autoimmunity

Gilchrist JJ. et al, (2021)

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2021), Nature medicine

Symptom study app provides real-world data on COVID-19 vaccines.

Drury RE. and O'Connor D., (2021), Lancet Infect Dis

Reducing COVID-19 vaccine hesitancy: a randomised controlled trial of the effects of different types of vaccination information (Oxford Coronavirus Explanations, Attitudes, and Narratives Survey (OCEANS) III).

FREEMAN D., (2021), Lancet Public Health

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.

Ogbe A. et al, (2021), Nat Commun, 12

Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study.

Korsten K. et al, (2021), The European respiratory journal, 57

How can community engagement in health research be strengthened for infectious disease outbreaks in Sub-Saharan Africa? A scoping review of the literature.

Vanderslott S. et al, (2021), BMC Public Health, 21

Antibody evasion by the P.1 strain of SARS-CoV-2.

Dejnirattisai W. et al, (2021), Cell

Identification of novel locus associated with coronary artery aneurysms and validation of loci for susceptibility to Kawasaki disease.

Hoggart C. et al, (2021), Eur J Hum Genet

RNA2HLA: HLA-based quality control of RNA-seq datasets

Chelysheva I. et al, (2021), Briefings in Bioinformatics

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.

Madhi SA. et al, (2021), N Engl J Med

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.

Wouters OJ. et al, (2021), Lancet, 397, 1023 - 1034

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?